NAV

RAPA-501-Allo

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
RAPA-501-Allo
Accession Number
DB15890
Description

RAPA-501-ALLO is composed of T-cells extracted from healthy volunteers; these cells are then reprogrammed ex vivo in a process that involves de-differentiation and re-differentiation.1

Type
Biotech
Groups
Investigational
Biologic Classification
Cell transplant therapies
Other cell transplant therapies
Synonyms
Not Available
External IDs
  • RAPA-501-Allo

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action

The hybrid TREG and Th2 phenotype of these cells inhibits the inflammatory pathways of COVID-19 through modulation of cytokines and chemokines and cross-regulation of Th1 and Th17 populations. This therapy also has been seen to mediate protection on lung alveolar tissue. The immunomodulation that occurs is in a T-cell receptor independent manner. Currently, RAPA-501-ALLO is being investigated against COVID-19.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. U.S. National Library of Medicine Clinical Trials: RAPA-501-Allo Off-the-Shelf Therapy of COVID-19 [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / Severe COVID-19 Disease1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on September 30, 2020 10:31 / Updated on October 01, 2020 12:55